Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Palatin Technologies Inc (PTN)
NYSE MKT:PTN
RESEARCH TOOLSreports
Palatin Technologies (PTN) Stock Price & Analysis
2,239 Followers
PTN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.43 - $6.40
Previous Close$1.51
Volume118.29K
Average Volume (3M)91.55K
Market Cap
$18.04M
Enterprise Value$8.11M
Total Cash (Recent Filing)$10.98M
Total Debt (Recent Filing)$1.05M
Price to Earnings (P/E)-0.6
Beta1.37
Next Earnings
Nov 13, 2023EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.53
Shares Outstanding11,946,646
10 Day Avg. Volume94,576
30 Day Avg. Volume91,548
Standard Deviation0.21
R-Squared0.06
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-46.66
Price to Sales (P/S)15.09
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.42
Enterprise Value/Gross Profit1.67
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$60.00Price Target Upside3873.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Palatin Technologies News
Pre-EarningsPalatin (PTN) Q4 Earnings Cheat Sheet
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PTN FAQ
What was Palatin Technologies Inc’s price range in the past 12 months?
Palatin Technologies Inc lowest stock price was $1.43 and its highest was $6.40 in the past 12 months.
What is Palatin Technologies Inc’s market cap?
Currently, no data Available
When is Palatin Technologies Inc’s upcoming earnings report date?
Palatin Technologies Inc’s upcoming earnings report date is Nov 13, 2023 which is in 43 days.
How were Palatin Technologies Inc’s earnings last quarter?
Palatin Technologies Inc released its earnings results on Sep 28, 2023. The company reported -$0.91 earnings per share for the quarter, missing the consensus estimate of -$0.527 by -$0.383.
Is Palatin Technologies Inc overvalued?
According to Wall Street analysts Palatin Technologies Inc’s price is currently Undervalued.
Does Palatin Technologies Inc pay dividends?
Palatin Technologies Inc does not currently pay dividends.
What is Palatin Technologies Inc’s EPS estimate?
Palatin Technologies Inc’s EPS estimate is -$0.41.
How many shares outstanding does Palatin Technologies Inc have?
Palatin Technologies Inc has 11,946,646 shares outstanding.
What happened to Palatin Technologies Inc’s price movement after its last earnings report?
Palatin Technologies Inc reported an EPS of -$0.91 in its last earnings report, missing expectations of -$0.527. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Palatin Technologies Inc?
Among the largest hedge funds holding Palatin Technologies Inc’s share is Fortress Investment Group LLC. It holds Palatin Technologies Inc’s shares valued at 739.
---
Palatin Technologies Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$60.00 (3873.51% Upside)
$60.00 (3873.51% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.70%
12-Months-Change
Fundamentals
Return on Equity
-335.84%
Trailing 12-Months
Asset Growth
-50.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Palatin Technologies Inc
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
---
Top 5 ETFs holding PTN
Vanguard Total Stock Market ETF
$508.21K
Up to five ETFs with an Outperform Smart Score that hold PTN. The ETFs are listed according to market value of PTN within the ETF
Aclaris Therapeutics
―
Axsome Therapeutics
―
Bio-Path Holdings
―
Eton Pharmaceuticals
―
---